Leading Element Driving Change in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market in 2025: Rising Obesity Prevalence Driving Growth In The Market Driver

What market dynamics are playing a key role in accelerating the growth of the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market is anticipated to grow owing to the escalating prevalence of obesity. Obesity, defined by a body mass index (BMI) of 30 or more, is a health condition typified by an unwanted buildup of body fat that can adversely affect one's general health. Due to unhealthy diets, inactive lifestyles, and metabolic risks, the global occurrence of obesity is on an uphill climb. Targeted therapies and lifestyle modifications that emphasize improving metabolic health, curbing liver fat, and managing insulin resistance are key components of MASH treatment in obesity cases. As reported by the World Heart Foundation, a Switzerland-based global non-government cardiovascular community, in March 2023, about 2.3 billion adults and children globally are either obese or overweight. With the current trend in obesity, this estimate is speculated to surge to 2.7 billion by 2025. Consequently, the rising prevalence of obesity fuels the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.

Get Your Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/metabolic-dysfunction-associated-steatohepatitis-mash-treatment-global-market-report

How will the growth rate of the metabolic dysfunction-associated steatohepatitis (mash) treatment market shape industry trends by 2034?
In recent times, there has been a significant escalation in the market size for the treatment of Metabolic-Dysfunction Associated Steatohepatitis (MASH). The market is expected to expand from $2.00 billion in the year 2024 to approximately $2.60 billion by 2025, progressing at a Compound Annual Growth Rate (CAGR) of 30.0%. The historical growth can be credited to the increasing cases of non-alcoholic steatohepatitis, prevailing modern dietary habits involving high consumption of processed foods, inactive lifestyles, and a growing prevalence of metabolic disorders.

The market size for treatment of metabolic dysfunction-associated steatohepatitis (MASH) is projected to experience a significant surge in the coming years. It is estimated to reach a value of $7.38 billion in 2029, with a compound annual growth rate (CAGR) of 29.8%. This growth during the forecasted period is expected to be driven by increasing rates of obesity and related health conditions, early detection and intervention, health insurance coverage, reimbursement policies, and a heightened awareness about liver diseases. Notable trends predicted for this period include growth in technological innovations, pipeline expansion, strategic alliances and partnerships, growth in personalised medicine and precision therapeutics, as well as increased funding in clinical trials and research.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp

What trends are poised to drive the future success of the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
Leading corporations within the metabolic dysfunction-associated steatohepatitis (MASH) treatment industry are concentrating their efforts on creating inventive items like liver fibrosis therapy solutions. These solutions are designed to offer treatment possibilities for individuals with MASH and moderate to severe liver fibrosis. The approach of these treatments is to address the root causes of liver damage through lifestyle changes, antiviral drugs, and upcoming antifibrotic therapies, with the primary aim of stopping or reversing fibrosis development and enhancing liver function. For example, Madrigal Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, declared in March 2024 that the FDA had approved Rezdiffra (resmetirom), the first-ever treatment for MASH with moderate to severe liver fibrosis. This oral tablet is taken daily and has shown its effectiveness in resolving MASH without worsening fibrosis and bettering liver fibrosis during phase 3 clinical tests. This breakthrough provides a non-invasive treatment option, negating the need for liver biopsies, and considerably enhances patient outcomes and access in managing fatty liver disease.

Which primary segments of the metabolic dysfunction-associated steatohepatitis (mash) treatment market are driving growth and industry transformations?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented -

1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20876

Which geographical regions are pioneering growth in the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the influential players reshaping the metabolic dysfunction-associated steatohepatitis (mash) treatment market landscape?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp

What Is Covered In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report?

•Market Size Forecast: Examine the metabolic dysfunction-associated steatohepatitis (mash) treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the metabolic dysfunction-associated steatohepatitis (mash) treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the metabolic dysfunction-associated steatohepatitis (mash) treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the metabolic dysfunction-associated steatohepatitis (mash) treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the metabolic dysfunction-associated steatohepatitis (mash) treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the metabolic dysfunction-associated steatohepatitis (mash) treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the metabolic dysfunction-associated steatohepatitis (mash) treatment market.
•Competitive Landscape: Review strategic developments in the metabolic dysfunction-associated steatohepatitis (mash) treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.